- Home
- LE vs KROS Comparison
LE vs KROS Comparison
Compare LE & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LE | KROS |
|---|---|---|
| Founded | 1963 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 550.2M | 584.9M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LE | KROS |
|---|---|---|
| Price | $16.58 | $14.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $32.50 | $23.00 |
| AVG Volume (30 Days) | 192.4K | ★ 274.3K |
| Earning Date | 03-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 104.89 | 3.85 |
| EPS | N/A | ★ 2.68 |
| Revenue | ★ $1,154,442,000.00 | N/A |
| Revenue This Year | $1.55 | $6,898.87 |
| Revenue Next Year | $2.38 | N/A |
| P/E Ratio | ★ N/A | $5.29 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.65 | $9.12 |
| 52 Week High | $20.04 | $22.55 |
Technical Indicators
Market Signals| Indicator | LE | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 46.73 | 20.82 |
| Support Level | $13.72 | $13.42 |
| Resistance Level | $16.57 | $15.02 |
| Average True Range (ATR) | 1.01 | 0.61 |
| MACD | -0.30 | -0.21 |
| Stochastic Oscillator | 21.80 | 6.79 |
Price Performance
Historical ComparisonAbout LE Lands' End Inc.
Lands' End Inc is a United States-based multi-channel retailer of casual clothing, accessories, and footwear, as well as home products. The company's operating segment includes U.S. eCommerce; International; Outfitters; Third Party and Retail. It generates maximum revenue from the U.S. eCommerce segment. The U.S. eCommerce segment offers products through the company's eCommerce website. Geographically operates in USA, Europe, Asia, it derives a majority of its revenue from the United States.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.